Literature DB >> 9572488

Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages.

M Matsuoka1, K Tani, S Asano.   

Abstract

The mechanism of cell cycle arrest induced by interferon-alpha (IFN-alpha) was analysed using a mouse macrophage cell line, BAC1.2F5A. IFN-alpha added in media before mid-G1 prohibited cells from entering S phase. The blockage of G1/S transition was associated with diminuition of both cyclin D1/cdk4- and cyclin E/cdk2-associated kinase activities. G1 cyclin-associated kinase activities were down-regulated quickly after the addition of IFN-alpha. Cells treated with IFN-alpha contained excess amounts of cdk inhibitors which down-regulated G1 cyclin/cdk-associated kinase activities in the proliferating cells and this action was counteracted by exogenously-supplied recombinant cyclin D2/cdk4 complexes. In parallel, accumulation of p19Ink4D and p21Cip1, and their attachment to cdks were up-regulated quickly after the addition of IFN-alpha. Expression of p19Ink4D and p21Cip1 was potentiated transcriptionally. We concluded that increased attachment of up-regulated cdk inhibitors including p19Ink4D and p21Cip1 to G1 cyclin/cdk complexes contributed to diminuition of G1 cyclin/cdk-associated kinase activities and resulting G1 phase arrest during the early phase of treatment with IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572488     DOI: 10.1038/sj.onc.1201745

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Authors:  Martina Musella; Gwenola Manic; Ruggero De Maria; Ilio Vitale; Antonella Sistigu
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

Review 2.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094

3.  Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells.

Authors:  A Swarbrick; C S Lee; R L Sutherland; E A Musgrove
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 4.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

5.  Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis.

Authors:  Brian Webster; Silke Wissing; Eva Herker; Melanie Ott; Warner C Greene
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

6.  Claudin 13, a member of the claudin family regulated in mouse stress induced erythropoiesis.

Authors:  Pamela D Thompson; Hannah Tipney; Andy Brass; Harry Noyes; Steve Kemp; Jan Naessens; May Tassabehji
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

7.  Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity.

Authors:  Sara Heil Peterson; Dean T Nardelli; Thomas F Warner; Steven M Callister; Jose R Torrealba; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-03-14

8.  Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements.

Authors:  Latifa Al-Haj; Perry J Blackshear; Khalid S A Khabar
Journal:  Nucleic Acids Res       Date:  2012-06-19       Impact factor: 16.971

9.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

10.  Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children.

Authors:  Stephen J Popper; Aubree Gordon; Minghsun Liu; Angel Balmaseda; Eva Harris; David A Relman
Journal:  PLoS Negl Trop Dis       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.